An established antiviral medicine that has been on the market in Europe since 2005 to treat people with HIV-1 is being recommended for disease prevention as well. Truvada, which contains the active substances emtricitabine and tenofovir disoproxil, has received a positive opinion from the European Medicines Agency for use as pre-exposure prophylaxis, together with safer sex practices.
